A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

Southampton's children's intensive care to feature in Channel 4 documentary

Description
Patients, staff and families from the paediatric intensive care unit at Southampton Children's Hospital are set to feature in a Channel 4 documentary on medical ethics.
Url
/AboutTheTrust/Newsandpublications/Latestnews/2018/March-2018/Southampton's-children's-intensive-care-to-feature-in-Channel-4-documentary.aspx

City's Princess Anne Hospital to feature in One Born Every Minute spin-off

Description
Staff, parents and children who starred in the first two series of Channel 4's hit maternity documentary One Born Every Minute are set to return to the nation's screens this week.
Url
/AboutTheTrust/Newsandpublications/Latestnews/2017/April-2017/Citys-Princess-Anne-Hospital-to-feature-in-One-Born-Every-Minute-spin-off.aspx

Featured research: ImmunoCOVID19 study

Description
Auto Generated Title Psychological sub-study (added 04/08/2021) For the past year you have kindly provided us with information on how the COVID pandemic impacted the physical health of immunosuppressed children and young people. Your comments and concerns have shown us that the uncertainty of the pandemic and the COVID restrictions have impacted your social life, education, and employment, and for some of you, your mental wellbeing. Therefore we are looking to add a new part to our study to assess your quality of life and the feelings you experience during these uncertain times. We will send all participants in this study an email inviting them to take part in this sub-study. If you participate, we will send you a short 10-minute survey to complete in September 2021, December 2021, and March 2022. To learn more about this new part of the study and how you can participate, please read the information in the forms below and follow the instructions in the email you have received. Patient information sheet for parents Patient information sheet for child 16-18 years Patient information sheet for child 12-16 years Patient information sheet for child 8-12 years Patient information sheet for child younger than 8 years If there are any questions don ’ t hesitate to email us at immunoCOVID19study@uhs.nhs.uk COVID serology sub-study (a dded 14/12/2020) From December onwards we are looking to add serology antibody tests to our study. To see if patients have been exposed to COVID we will send everyone who wants to participate a sampling kit with instructions on how to take a finger prick blood sample at home. We will send all participants in this study an email inviting them to take part in this sub-study. If you want to participate, please read the information in the forms below and follow the instructions in the email you have received. Patient information sheet 16 years and older Patient information sheet 12-16 years Patient information sheet 8-12 years Patient information sheet younger than 8 years If there are any questions don ’ t hesitate to email us at immunoCOVID19study@uhs.nhs.uk Study to monitor COVID-19 infections in children and adults possibly more vulnerable for infections This study does not replace your normal healthcare provision. If you or your child becomes unwell during the course of the study you should seek medical advice via emergency health care providers, call NHS 111 or contact your child ’ s normal clinical team. If you or your child has any symptoms that could possibly be due to coronavirus infection please follow the guidance here . Thank you for considering taking part in this online study, in which we aim to monitor adults, children and young people who have a condition that make them more vulnerable to infections or are taking medication that affects their immune system during this coronavirus epidemic. This is a multi-centre study in which more than 30 other hospitals are participating ( see ful list of sites ). Southampton is coordinating the study but children/parents from other hospitals can participate once their consultant has notified the study team in Southampton. It is important to stress that the information currently available from the most severely affected countries suggests that these conditions and drugs do not seem to affect the response to coronavirus in children. Adults in these medications may be at increased risk of severe COVID-19 infection but no detailed information is yet available. Many families have expressed concern about what impact the virus will have and we would like to collect data to enable us to give you more informed advice. The study will consist of a weekly questionnaire that takes less than 10 minutes to fill in. For more information please read the following information: For parents/carers and children 16-17 years old For children under 16 years old For adult patients For information about data protection For children <16 assent form We will ask for consent from parents for children less than 16 years or from children aged 16-17 years and adults, on the online study website before filling in the study questionnaires. Children less than 16 years old will be asked to sign the assent form during their next planned clinic visit. If you would like to help us and have received a link to the online study, please click on that link to start the study. If you would like to participate but have not received a link: For University Hospital Southampton patients email: UHS.recruitmentCRF@nhs.net and include “ immunoCOVID19 ” , name of your child or you own name if you are 16 or older, DOB and clinical team caring for your child ’ s condition For other hospitals you will need to contact the consultant who is taking care of your or your child ’ s condition. If you have any study related queries you can email: immunoCOVID19study@uhs.nhs.uk Please continue with your medication unless you are advised to stop by the clinical team caring for your or your child ’ s condition. Up to date information about Coronavirus and what you need to do can be found here .
Url
/ClinicalResearchinSouthampton/Public-and-patients/Featured-research-studies/Featured-research-ImmunoCOVID19-study.aspx

Featured research: MS-STAT2 study

Description
Auto Generated Title Is Simvastatin an effective treatment for Secondary Progressive Multiple Sclerosis (SPMS)? How does it work? Simvastatin is one of a group of statin medications currently used to treat high cholesterol. A team of researchers at University College London (UCL) investigated the effect of Simvastatin in a small phase 2 trial (MS-STAT1) and found that not only did it improve levels of disability and slow down progression of disease, it also reduced the rate of brain atrophy (shrinkage) which suggests that it may also have a role in protecting nerves from damage. At the moment there are no treatments available to slow or stop the disability associated with Multiple Sclerosis (MS). If this trial is successful, Simvastatin could become one of the first ever licensed treatments for SPMS! The race is on! The COVID-19 pandemic has had a huge impact on our ability to recruit people to the MS-STAT2 trial and we now only have a couple of months to recruit as many people as possible to the trial. This is such an exciting opportunity for people with SPMS that we want to make sure that as many people as possible know about the trial and know what ’ s involved should they wish to take part! So what ’ s involved? If you express an interest in taking part, you will initially be contacted by the Southampton MS trial team to check that you are eligible. The main inclusion criteria are: A confirmed diagnosis of SPMS Aged between 25-65 An EDSS score of 4.0- 6.5 (inclusive) Once we have confirmed eligibility, you will then be invited to attend a screening and baseline appointment where we will discuss the trial and gather some information about your MS, medication you may currently taking and what your mobility is like. We will take some blood and also ask you a number of questions via self reported questionnaires. These help us to measure how you manage your day to day life with SPMS and how that might change over the course of the trial. You will then be seen by the trial team every 6 months for the 3 year duration of the trial. At each visit we will take some bloods to make sure that you are well on the trial and take some objective measures. For example, we will test your walking with a timed walk test and your upper limb function using the 9 hole peg test. If you find that travelling to Southampton every 6 months is too time consuming we can now offer a virtual visit at each 6 month point meaning you only need to see us annually. Joining a trial is a shared decision between the research team who provide all the trial information and the participant. Ultimately it is up to you if you want to take part and requesting information on the trial doesn ’ t commit you in any way. Contact us If you are interested in taking part and think you might be eligible, please contact the MS research team on neuroms@uhs.nhs.uk for an initial discussion
Url
/ClinicalResearchinSouthampton/Public-and-patients/Featured-research-studies/Featured-research-MS-STAT2-study.aspx

Featured research: COVID-19 vaccine trial in adolescents

Description
Auto Generated Title The University Hospital Southampton NHS Foundation Trust are inviting healthy adolescents aged 12 to 17 years old to participate in a COVID-19 vaccine study. This study will provide information vital to the development of a new vaccine to protect against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), this virus causes a disease called COVID-19. This study will test the experimental vaccine to help scientists and doctors find out if it can help prevent disease caused by the virus. The main purpose of this study is to see if the study vaccine is safe (if it causes any side effects) and how people feel after the vaccine. You will be reimbursed for travel and meal expenses. Who can take part? If you / your child are aged 12-17 and in good health you may be eligible to take part What does this study involve? The study consists of: 11 visits in clinic and some telephone follow-up over a 19-month period Vaccination with 2 doses and a booster dose of COVID-19 Vaccine or placebo You will be reimbursed for travel and meal expenses You can download the relevant documents below: Patient information sheet Parent/legal guardian information sheet To take part For more information, please visit www.uhs.nhs.uk/nihr-crf . You can also contact the Project management team on 02381 203853 or email uhs.covid19paedvaccinestudies@nhs.net
Url
/ClinicalResearchinSouthampton/Public-and-patients/Featured-research-studies/Featured-research-COVID-19-vaccine-trial-in-adolescents.aspx

Featured research: UK-REACH

Description
Auto Generated Title The United Kingdom Research study into Ethnicity And COVID-19 outcomes in Healthcare workers (UK-REACH) is being undertaken to understand if, how, and why, ethnicity affects COVID-19 clinical outcomes in healthcare workers (HCWs). The study will also investigate the impact of COVID-19 on the physical and mental health of HCWs, primarily those from an ethnic minority background. Why have I been invited to take part? You have been invited to take part because we want to hear from people of all ethnicities working in health and social care during COVID-19. You do not need to have had COVID-19 to join the study. We are especially keen to hear from people from ethnic minorities to understand why and how some groups have been particularly affected by the pandemic and their experiences of working in health care settings through this pandemic. We are inviting people from all job roles to participate in this study. You do not need to look after patients directly to join the study. What will taking part involve? We are inviting health and social care workers to participate in Work Package 2 and/or Work Package 4 of our study: Work Package 2: We will establish a national longitudinal cohort of ethnic minority (with White ethnic group as comparator) HCWs and ancillary staff working in healthcare settings and assess changes in their health outcomes, social circumstances and professional roles over the course of forthcoming pandemic waves and beyond. Work Package 4: We will undertake qualitative interviews and focus group discussions (FGDs) with ethnic minority HCWs to understand risk perceptions, support and coping mechanisms in relation to COVID-19. You could be part of the cohort study in Work Package 2 which entails filling an online questionnaire, and you could also participate in a qualitative interview or group discussion in Work package 4. Alternately, you could choose only to participate in either one of the work packages. If you are a key staff opinion leader working in a health care organisation (e.g. GMC, Royal Colleges), we also invite you to participate in the in-depth interviews held under Work package 3: Work Package 3: We will undertake research to understand and address legal, ethical and acceptability issues around data protection, privacy and information governance associated with the linkage of professionals' registration data and healthcare data. Participation in the study is voluntary. It is up to you to decide whether or not to take part. If you do decide to take part you will be asked to sign a consent form. However, agreeing to participate does not oblige you to remain in the study and you may withdraw from the study at any time and without giving a reason. How will the study results help protect minority ethnic groups? We believe our work will be of direct relevance to policy-makers and professional organisations, providing evidence to inform responses to the current/future COVID-19 pandemic waves, as well as a framework within which we are able to investigate longer-term clinical outcomes on physical and mental health. Our research is designed to identify key risk factors that may contribute to elevated morbidity and mortality in ethnic minority staff in healthcare settings as well as increased knowledge about access to support and key coping mechanisms to protect the mental and physical health of staff working in these settings. These will, in turn, inform a set of recommendations for protection of ethnic minority healthcare workers from COVID-19 related morbidity and mortality. You can find out more about the study on the UK-REACH website , including FAQs , or contact the lead research team at uk-reach@leicester.ac.uk .
Url
/ClinicalResearchinSouthampton/Public-and-patients/Featured-research-studies/Featured-research-UK-REACH.aspx

Featured research: COVID-19 vaccine trial

Description
Auto Generated Title Healthy adults aged 18-55 can now contribute to the world's search for an effective COVID-19 vacine by joining a trial of the candidate COVID-19 vaccine ChAdOx1 nCoV-19 at Southampton. Please contact uhs.recruitmentCRF@nhs.net for more information. Developed by clinical teams at the University of Oxford ’ s Jenner Institute and Oxford Vaccine Group, the vaccine is being tested for how strongy it stimulates the body's immune defences, protects against infection and its safety. The study will involve up to 510 healthy volunteers between 18 and 55 with around 187 participants to be recruited at University Hospital Southampton. ChAdOx1 nCoV-19 a is made from a weakened version of a common cold virus (adenovirus) from chimpanzees that has been genetically changed so that it is impossible for it to grow in humans. This has been combined with genes that make proteins from the COVID-19 virus (SARS-CoV-2) called spike glycoprotein which play an essential role in allowing the SARS-CoV-2 virus to attach to and enter the body's cells. By vaccinating with ChAdOx1 nCoV-19, experts hope to turn the virus' spikes against it. By raising antibodies that stick to them it turns them into targets for the immune system to lock onto and destroy it, helping to stop the virus from entering human cells and therefore preventing infection. To find out more about the study and how to take part, contact uhs.recruitmentCRF@nhs.net
Url
/ClinicalResearchinSouthampton/Public-and-patients/Featured-research-studies/Featured-research-COVID-19-vaccine-trial.aspx

Featured research studies

Description
Public and patients Auto Generated Title In this section, you will find out about some of the large research studies we're conducting, and how you can get involved from menu on the left.
Url
/ClinicalResearchinSouthampton/Public-and-patients/Featured-research-studies/Featured-research-studies.aspx

Featured research: Tackling whooping cough

Description
Auto Generated Title The NIHR Wellcome Trust Clinical Research Facility at the Southampton General Hospital is taking part in a new study, aiming to develop better understanding of how to prevent whooping cough. Whooping cough Whooping cough, also called pertussis, is a bacterial infection of the lungs and airways. It is caused by a bacterium called Bordetella pertussis ( B. pertussis ). Whooping cough can cause repeated coughing bouts that can last for two to three months or more. Young babies under six months of age are typically affected and are in the age group that is most vulnerable to serious complications. In older children and adults it tends to be less serious, although it can still be unpleasant and frustrating. B. pertussis is spread in the droplets produced when someone with the infection coughs or sneezes. Therefore you can catch whooping cough if you come into close contact with someone with the infection. The first symptoms are similar to those of a cold. Intense coughing bouts typically start about a week later. Antibiotics will help stop the infection spreading to others, and usually ( but do not always ) reduce the symptoms. If antibiotics are given during the early phase of the infection, it is believed that the cough can be prevented, but there are exceptions to this rule and it is possible that people who are given antibiotics even during the early phase of illness may go on to develop the cough. Although a pertussis vaccine is offered to all babies in the UK, the vaccine does not offer lifelong protection. In fact, protection by the vaccine seems to be less nowadays in comparison to 15 years ago. Better prevention This study is part of a project that aims to develop a better vaccine against whooping cough. To do this we need to know more about the immune response generated against B. pertussis and what kind of immune response protects against whooping cough. This study is designed to look at those particular questions by inoculating healthy volunteers with nose drops containing B. pertussis , then monitoring their immune response before giving them an antibiotic to clear B. pertussis .
Url
/ClinicalResearchinSouthampton/Public-and-patients/Featured-research-studies/Featured-research-Help-us-tackle-whooping-cough.aspx

City's neonatal unit features in new premature baby TV ad

Description
Patients, parents and staff in the neonatal unit at Southampton's Princess Anne Hospital are the stars of a new TV ad campaign which promotes the development of a pioneering tiny nappy for premature babies.
Url
/AboutTheTrust/Newsandpublications/Latestnews/2017/May-2017/Citys-neonatal-unit-features-in-new-premature-baby-TV-ad.aspx
1 to 10 of 204
Previous 1 2 3 4 5 … Next